If you're using Tinder to hook up, or even just meet people and really watch Netflix, check out the Healthvana app in the Safety part of the menu. It can help you find an STI clinic nearby and get yourself tested. Knowing your status is the #1 way to protect your reproductive health. Many STIs are asymptomatic in women. This makes it especially important to do your own testing.
Dr. Jeffrey Klausner, MPH joined me to talk about the Helathvana app. He is a public health superstar. I suggest you listen to him.
Showing posts with label std. Show all posts
Showing posts with label std. Show all posts
Tuesday, February 16, 2016
Wednesday, December 30, 2015
CytoDyn HIV Drug Drops Viral Load to Non-Detectable Levels in Testing
Dr. Nader Pourhassan, CEO of CytoDyn Inc, talked with me about their HIV drug, PRO 140, which has had demonstrated remarkable effect on patients in FDA IRB approved tests.
About PRO 140
PRO 140 belongs to a new class of HIV/AIDS therapeutics -- viral-entry inhibitors -- that are intended to protect healthy cells from viral infection. PRO 140 is a fully humanized IgG4 monoclonal antibody directed against CCR5, a molecular portal that HIV uses to enter T-cells. PRO 140 blocks the predominant HIV (R5) subtype entry into T-cells by masking this required co-receptor, CCR5. Importantly PRO 140 does not appear to interfere with the normal function of CCR5 in mediating immune responses. PRO 140 does not have agonist activity towards CCR5 but does have antagonist activity to CCL5 which is a central mediator in inflammatory diseases. PRO 140 has been the subject of seven clinical trials, each demonstrating efficacy by significantly reducing or controlling HIV viral load in human test subjects. PRO 140 has been designated a "fast track" product candidate by the FDA. The PRO 140 antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements as compared to daily drug therapies currently in use.
PRO 140 belongs to a new class of HIV/AIDS therapeutics -- viral-entry inhibitors -- that are intended to protect healthy cells from viral infection. PRO 140 is a fully humanized IgG4 monoclonal antibody directed against CCR5, a molecular portal that HIV uses to enter T-cells. PRO 140 blocks the predominant HIV (R5) subtype entry into T-cells by masking this required co-receptor, CCR5. Importantly PRO 140 does not appear to interfere with the normal function of CCR5 in mediating immune responses. PRO 140 does not have agonist activity towards CCR5 but does have antagonist activity to CCL5 which is a central mediator in inflammatory diseases. PRO 140 has been the subject of seven clinical trials, each demonstrating efficacy by significantly reducing or controlling HIV viral load in human test subjects. PRO 140 has been designated a "fast track" product candidate by the FDA. The PRO 140 antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements as compared to daily drug therapies currently in use.
Subscribe to:
Posts (Atom)